|Bid||15.75 x 800|
|Ask||15.90 x 900|
|Day's range||14.15 - 15.77|
|52-week range||9.72 - 33.97|
|Beta (5Y monthly)||0.69|
|PE ratio (TTM)||N/A|
|Earnings date||22 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||31.56|
Thanks to the dual headwinds of sky-high inflation and the threat of rising interest rates, biopharmaceutical stocks appear poised for a turbulent 2022. Underscoring this point, investors have been dumping risky clinical and early commercial-stage biopharma stocks over the past several weeks in response to these closely intertwined macro variables. This year thus seems destined to be a bona fide "stock-picker's market" for biopharma investors.
VICTORIA, British Columbia, January 04, 2022--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the "Company") today announced that members of the management team will participate in two upcoming virtual investor conferences.
Investors need to pay close attention to CorMedix (AUPH) stock based on the movements in the options market lately.